195 related articles for article (PubMed ID: 30222105)
1. A novel pH-dependent membrane peptide that binds to EphA2 and inhibits cell migration.
Alves DS; Westerfield JM; Shi X; Nguyen VP; Stefanski KM; Booth KR; Kim S; Morrell-Falvey J; Wang BC; Abel SM; Smith AW; Barrera FN
Elife; 2018 Sep; 7():. PubMed ID: 30222105
[TBL] [Abstract][Full Text] [Related]
2. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
3. Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor.
Westerfield JM; Sahoo AR; Alves DS; Grau B; Cameron A; Maxwell M; Schuster JA; Souza PCT; Mingarro I; Buck M; Barrera FN
J Mol Biol; 2021 Sep; 433(18):167144. PubMed ID: 34229012
[TBL] [Abstract][Full Text] [Related]
4. EphA2 Transmembrane Domain Is Uniquely Required for Keratinocyte Migration by Regulating Ephrin-A1 Levels.
Ventrella R; Kaplan N; Hoover P; Perez White BE; Lavker RM; Getsios S
J Invest Dermatol; 2018 Oct; 138(10):2133-2143. PubMed ID: 29705292
[TBL] [Abstract][Full Text] [Related]
5. Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.
Tawadros T; Brown MD; Hart CA; Clarke NW
Br J Cancer; 2012 Nov; 107(10):1737-44. PubMed ID: 23037715
[TBL] [Abstract][Full Text] [Related]
6. A role of the SAM domain in EphA2 receptor activation.
Shi X; Hapiak V; Zheng J; Muller-Greven J; Bowman D; Lingerak R; Buck M; Wang BC; Smith AW
Sci Rep; 2017 Mar; 7():45084. PubMed ID: 28338017
[TBL] [Abstract][Full Text] [Related]
7. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
8. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
9. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
10. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size.
Zapata-Mercado E; Biener G; McKenzie DM; Wimley WC; Pasquale EB; Raicu V; Hristova K
J Biol Chem; 2022 Oct; 298(10):102370. PubMed ID: 35970390
[TBL] [Abstract][Full Text] [Related]
12. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility.
Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846
[TBL] [Abstract][Full Text] [Related]
13. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Wykosky J; Gibo DM; Debinski W
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715
[TBL] [Abstract][Full Text] [Related]
14. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.
Greene AC; Lord SJ; Tian A; Rhodes C; Kai H; Groves JT
Biophys J; 2014 May; 106(10):2196-205. PubMed ID: 24853748
[TBL] [Abstract][Full Text] [Related]
15. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
16. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
17. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines.
Lohmüller T; Xu Q; Groves JT
Nano Lett; 2013 Jul; 13(7):3059-64. PubMed ID: 23668885
[TBL] [Abstract][Full Text] [Related]
19. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.
Singh DR; Pasquale EB; Hristova K
Biochim Biophys Acta; 2016 Sep; 1860(9):1922-8. PubMed ID: 27281300
[TBL] [Abstract][Full Text] [Related]
20. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
Himanen JP; Goldgur Y; Miao H; Myshkin E; Guo H; Buck M; Nguyen M; Rajashankar KR; Wang B; Nikolov DB
EMBO Rep; 2009 Jul; 10(7):722-8. PubMed ID: 19525919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
